Skip to main content
. 2016 Dec 16;6(12):e512. doi: 10.1038/bcj.2016.117

Table 2. Baseline clinical characteristics.

Baseline characteristics Overall (n=840) CPCs absent (n=678) CPCs present (n=162) P-value
Median age at transplant (range), years 61.1 (24.4–76.1) 61.4 (24.4–76.1) 59.9 (32.2–73.8) 0.068
Males (%) 59.6 61.2 53.1 0.060
         
ISS stage, n (%)       0.004
 Stage I 161 (19.2) 143 (21.1) 18 (11.1)  
 Stage II 313 (37.3) 257 (37.9) 56 (34.6)  
 Stage III 204 (24.3) 156 (23.0) 48 (29.6)  
 Missing 162 (19.3) 122 (18.0) 40 (24.7)  
         
Median time from diagnosis to transplant (range), months 6.1 (1.3–11.9) 6.1 (1.3–11.9) 6.3 (2.4–11.9) 0.215
         
FISH cytogeneticsa, n (%)       0.001
 High risk 191 (22.7) 138 (20.4) 53 (32.7)  
 Standard risk 551 (65.6) 453 (66.8) 98 (60.5)  
 Missing 98 (11.7) 87 (12.8) 11 (6.8)  
         
Pre-transplant response, n (%)       <0.001
 CR 136 (16.2) 128 (18.9) 8 (4.9)  
 VGPR 221 (26.3) 193 (28.5) 28 (17.3)  
 PR 346 (41.2) 284 (41.9) 62 (38.3)  
 MR or SD 93 (11.1) 57 (8.4) 36 (22.2)  
 PD 44 (5.2) 16 (2.4) 28 (17.3)  
         
Induction regimen
 PI-based only, n (%) 297 (35.4) 255 (37.6) 42 (25.9) 0.004
 IMiD-based only, n (%) 256 (30.5) 206 (30.4) 50 (30.9) 0.905
 PI- and IMiD-based, n (%) 277 (33.0) 211 (31.1) 66 (40.7) 0.021
         
Melphalan dose, n (%)       0.938
 Full 740 (88.1) 597 (88.1) 143 (88.3)  
 Reduced 100 (11.9) 81 (11.9) 19 (11.7)  
         
Post-transplant maintenance or consolidation, n (%) 321 (38.2) 262 (38.6) 59 (36.4) 0.600

Abbreviations: CPC, circulating plasma cell; CR, complete response; FISH, fluorescence in situ hybridization; IMiD, immunomodulator; ISS, International staging system; MR, minimal response; PD, progressive disease; PI, proteasome inhibitor; PR, partial response; SD, stable disease; VGPR, very good partial response.

a

High-risk FISH cytogenetics was defined by t(4;14), del(17p), t(14;16), t(14;20) and +1q.